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Abstract
Background: Several cellular positive and negative elongation factors are involved in regulating
RNA polymerase II processivity during transcription elongation in human cells. In recruiting several
of these regulatory factors to the 5' long terminal repeat (LTR) promoter during transcription
elongation, HIV-1 modulates replication of its genome in a process mediated by the virus-encoded
transactivator Tat. One particular cellular regulatory factor, DSIF subunit human SPT5 (hSpt5), has
been implicated in both positively and negatively regulating transcriptional elongation but its role in
Tat transactivation in vivo and in HIV-1 replication has not been completely elucidated.
Results: To understand the in vivo function of hSpt5 and define its role in Tat transactivation and
HIV-1 replication, we used RNA interference (RNAi) to specifically knockdown hSpt5 expression
by degrading hSpt5 mRNA. Short-interfering RNA (siRNA) designed to target hSpt5 for RNAi
successfully resulted in knockdown of both hSpt5 mRNA and protein levels, and did not significantly
affect cell viability. In contrast to hSpt5 knockdown, siRNA-mediated silencing of human mRNA
capping enzyme, a functionally important hSpt5-interacting cellular protein, was lethal and showed
a significant increase in cell death over the course of the knockdown experiment. In addition, hSpt5
knockdown led to significant decreases in Tat transactivation and inhibited HIV-1 replication,
indicating that hSpt5 was required for mediating Tat transactivation and HIV-1 replication.
Conclusions: The findings presented here showed that hSpt5 is a bona fide positive regulator of
Tat transactivation and HIV-1 replication in vivo. These results also suggest that hSpt5 function in
transcription regulation and mRNA capping is essential for a subset of cellular and viral genes and
may not be required for global gene expression.
Background
The elongation phase of transcription is often a critical
juncture for regulating gene expression [1,2] and a
number of genes including c-myc, c-fms, hsp70, and those
encoded by HIV-1 are regulated at this stage of transcrip-
tion [3-6]. During transcription elongation, shortly after
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successful initiation of RNA synthesis, RNA polymerase II
(RNA pol II) can pause, arrest, pass through terminator
sequences, or terminate transcription. The varying proces-
sivity of RNA pol II prior to entering productive elonga-
tion is controlled by the action of both negative and
positive transcription elongation factors (N-TEFs and P-
TEFs, respectively). The function of P-TEFs is to reduce the
barrier of N-TEFs and promote the release of RNA pol II
from the transition state that can cause termination of
transcription [7]. Three elongation regulatory factors, P-
TEFb (positive transcription elongation factor b), DSIF
(DRB (5,6-dichloro-1-β-D-ribofuranosylbenzimidazole)
sensitivity-inducing factor) and NELF (negative elonga-
tion factor), have been identified using DRB as a transcrip-
tion inhibitor [8-10] and function together to regulate
transcription elongation.
Modulation of HIV-1 gene expression provides one fun-
damental example of how transcription elongation can be
controlled by such regulatory factors [11-14]. Tat, an HIV-
1 regulatory protein, is required for synthesis of viral
mRNA and increases the efficiency of transcription elon-
gation from the HIV-1 promoter. In the presence of Tat,
the processivity of RNA Pol II complexes that initiate tran-
scription in the HIV-1 5' long terminal repeat (5' LTR)
region becomes greatly enhanced. For this increased
processivity to occur, Tat binds with a nascent leader RNA
element, trans-activation responsive (TAR) RNA, located
at the 5' end of all HIV-1 transcripts [15]. Cellular factors
in association with Tat and TAR are then recruited to the
5' LTR, stimulating RNA pol II processivity during elonga-
tion. More specifically, the C-terminal domain (CTD) of
RNA pol II is proposed to be hyperphosphorylated by P-
TEFb during Tat transactivation to promote elongation
[12-14]. Composed of cyclin-dependent kinase CDK9
and Cyclin T1, P-TEFb has been shown to bind the activa-
tion domain of Tat and TAR RNA loop sequence and
phosphorylate the CTD of RNA pol II [16-18]. Tat transac-
tivation is postulated to involve Tat-TAR interactions that
then give rise to the recruitment of P-TEFb to RNA pol II
complexes at the 5' LTR. This recruitment is necessary to
enhance the processivity of RNA Pol II from the HIV-1 5'
LTR promoter [7,14,17,19]. Thus, TAR RNA provides a
scaffold for Tat and P-TEFb to bind and assemble a regu-
latory switch during HIV replication [20].
Human DSIF consists of subunits hSpt5 and hSPT4 and
was originally discovered as a negative elongation factor
that binds to RNA pol II [9]. In conjunction with NELF,
DSIF represses transcriptional elongation at positions
proximal to promoters [9,10]. Escape from transcriptional
repression imposed by DSIF and NELF requires P-TEFb,
which has been shown in vitro to phosphorylate both
hSpt5 and CTD [7,10,21-29]. Interestingly, hSpt5 is con-
served among eukaryotes and is a dual transcriptional reg-
ulator that can function as both a negative and positive
elongation factor [30-32]. Currently, it is postulated that
phosphorylation of hSpt5 and RNA pol II by P-TEFb is the
key event during which hSpt5 functionally switches from
a negative barrier to a positive elongation factor during
transcription in human cells. Methylation of SPT5 also
has been shown to regulate its interaction with RNA pol II
and this posttranslational modification of SPT5 may alter
transcriptional elongation functions in response to viral
and cellular factors [33].
Although hSpt5's role in transcription regulation in asso-
ciation with P-TEFb has been established, its involvement
in Tat transactivation and HIV-1 replication continues to
be elucidated. Several in vitro studies have shown that
hSpt5 is required for Tat transactivation and that both
hSpt5 and RNA pol II phosphorylation is stimulated after
recruitment of P-TEFb by Tat [25,29,34]. hSpt5 may also
play a positive role in Tat transactivation through its asso-
ciation with human mRNA capping enzyme (HCE),
which is a bifunctional triphosphatase-guanylyltrans-
ferase required for capping mRNA (reviewed in [1,35]),
since SPT5, Tat, and CTD associate with the capping appa-
ratus to stimulate capping [36-43]. However, studies in a
recent report have suggested that only P-TEFb hyperphos-
phorylation of the RNA pol II CTD is directly required for
Tat transactivation, precluding a direct role for hSpt5 in
RNA pol II processivity during HIV-1 replication [26].
Therefore, hSpt5 role in Tat transactivation and HIV-1 rep-
lication in vivo remains unclear.
Here, we used RNA interference (RNAi) to address
whether hSpt5 is required for Tat transactivation and thus
HIV-1 replication in vivo and further defined hSpt5 cellu-
lar functions. RNAi is a remarkably efficient process
whereby double-stranded RNA (dsRNA) induces
sequence-specific degradation of homologous mRNA in
animal and plant cells (reviewed in ref. [44]). In mamma-
lian cells, RNAi can be triggered by 21-nucleotide (nt)
small interfering RNA (siRNA) duplexes and a few dsRNA
molecules are sufficient to inactivate a continuously tran-
scribed target mRNA for an observable period of time
[45,46]. RNAi has recently been used to successfully
knockdown the expression of a number of HIV genes,
including p24, reverse transcriptase, vif, nef, tat, and rev,
and has led to pre- and post-integrative HIV-1 RNA degra-
dation and reduced HIV infectivity [47-52]. These results
suggested that targeting viral factors required for the HIV
life cycle with siRNAs including those required for HIV
replication is a viable method for treating HIV infections.
Other groups have targeted cellular factors implicated in
supporting the HIV life cycle, including T-cell co-receptors
CD4, CXCR4, CCR5, and CD8 [50,52-54] and transcrip-
tion factor NF-κB [51], which has a role in HIV transcrip-
tion initiation. Knockdown of the co-receptors reduced
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HIV infectivity, effectively blocking HIV entry into cells
[55]. RNAi has become one of the leading methodologies
for studying gene knockdown in human cells. During
RNAi, a double-stranded 21-nucleotide (nt) short-inter-
fering RNA (siRNA) targets a specific, complementary
mRNA for degradation, resulting in significantly
decreased expression, or knockdown, of the targeted gene
(reviewed in [56,57]). In this report, siRNA designed to
target hSpt5 successfully silenced hSpt5 as observed by
decreased hSpt5 mRNA and protein expression. In addi-
tion, RNAi directed against hSpt5 did not significantly
affect cell viability. hSpt5 knockdown led to significant
decreases in Tat transactivation and inhibited HIV replica-
tion, indicating that hSpt5 was required for Tat transacti-
vation and HIV replication in vivo. Taken together,
silencing of hSpt5 by RNAi firmly established that the reg-
ulation of HIV-1 gene expression requires both Tat-TAR-P-
TEFb interactions and interactions between RNA pol II
transcription complexes and hSpt5.
Results
Specific silencing of hSpt5 expression by siRNA in HeLa 
cells
To inhibit hSpt5 expression in a cultured human cell line
using RNAi, siRNA targeting an hSpt5 sequence from
position 407 to 427 relative to the start codon was
designed (Figure 1A). Magi cells were transfected with this
hSpt5 duplex siRNA using Lipofectamine (Invitrogen). To
evaluate the effects of hSpt5 RNAi, total cell lysates were
prepared from siRNA-treated cells harvested at various
time points after transfection. hSpt5 mRNA or protein lev-
els were analyzed by RT-PCR or western blot using anti-
hSpt5 antibodies, respectively. Cells transfected with
hSpt5 siRNA had significantly lowered hSpt5 mRNA (Fig-
ure 1B, lane 3) and protein expression (Figure 1C, lane 3),
indicating that siRNA-mediated silencing of hSpt5 had
occurred successfully. hSpt5 knockdown was consistently
between ~85–90%. This knockdown effect was dependent
on the presence of the 21-nt siRNA duplex harboring a
sequence complementary to the mRNA target. As shown
in Figures 1B and 1C, mock-treated (no siRNA) (lane 1),
single-stranded antisense hSpt5 siRNA (lane 2), or mis-
matched hSpt5 duplex siRNA (lane 4) containing two
nucleotide mismatches between the target mRNA and
siRNA antisense strand at the putative cleavage site of the
target mRNA (Figure 1A) did not affect hSpt5 mRNA or
protein levels. These results showed that hSpt5 knock-
down was specific to duplex siRNA exactly complemen-
tary to the hSpt5 mRNA target. In evaluating either mRNA
or protein levels, human Cyclin T1 (hCycT1) was used as
an internal control, showing that the effects of hSpt5
siRNA were specific to hSpt5 and did not effect hCycT1
mRNA or protein expression (Figure 1B and 1C, lower
panel). Taken together, these results demonstrated that
hSpt5 knockdown was sequence specific and led to signif-
icantly decreased hSpt5 mRNA and protein levels.
Kinetics of hSpt5 knockdown by RNAi
Having established that hSpt5 could be knocked down
using RNAi, the kinetics of hSpt5 knockdown were exam-
ined. To perform kinetic experiments, hSpt5 duplex
siRNA, single-stranded antisense hSpt5 siRNA, or mis-
match duplex hSpt5 siRNA were transfected into Magi
cells. Cell lysates were collected at various time points to
assay for protein levels during hSpt5 knockdown. Immu-
noblot analysis using anti-hSpt5 antibodies revealed the
timing of gene suppression and persistence of hSpt5 RNAi
effects in Magi cells during the time course experiment
(Figure 2). hSpt5 knockdown was first observed between
30–42 h post-transfection, with maximum knockdown
(~85–90% knockdown) occurring at 42–66 h post trans-
fection (Figure 2, lane 8–14). Protein levels gradually
recovered to normal levels between 66–90 h (data not
shown), indicating that the effects of hSpt5 siRNA did not
last indefinitely. Neither single-stranded antisense siRNA
(Figure 2, lanes 1–7) nor mismatched duplex siRNA (Fig-
ure 2, lanes 15–21) affected hSpt5 protein levels through-
out the duration of the time course. These results
indicated that hSpt5 knockdown by RNAi occurred after
30 h and these knockdown effects were specific to duplex
siRNA targeting hSpt5.
Knockdown of hSpt5 is not lethal to human cells
Knowing that the kinetics of hSpt5 peaked at 42–54 h
post-transfection, we were able to evaluate the viability of
cells during hSpt5 knockdown experiments over varied
time intervals. Cell viability was assessed using trypan
blue exclusion at various times after a single transfection
of various siRNAs. As shown in Figure 3, during the 66 h
time course experiment, the number of non-viable hSpt5
knockdown cells (yellow line) observed was comparable
to mock-treated cells (no siRNA; dark blue line). Cells
transfected with single-stranded antisense hSpt5 siRNA
(purple line) or mismatched hSpt5 duplex siRNA (light
blue line) that did not show hSpt5 knockdown also
showed minimal changes in cell viability.
hSpt5 has been shown to interact with the human mRNA
capping enzyme (HCE) and this interaction enhances cap-
ping enzyme guanylylation and mRNA capping several
fold [40]. Since Spt5, Tat, and CTD associate with the cap-
ping apparatus to stimulate capping [36,37,39-42], we
planned to separately define the role of HCE and hSpt5 in
Tat transactivation by using RNAi to specifically knock-
down HCE expression. HCE knockdown was confirmed
by RT-PCR (data not shown). In contrast to hSpt5 knock-
down cells, HCE knockdown cells showed a significant
increase in cell death (Figure 3, red line) over the course
of the knockdown experiment. These results indicated
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Specific silencing of hSpt5 expression by RNAiFigure 1
Specific silencing of hSpt5 expression by RNAi. (A) hSpt5 mRNA is 3261 nucleotides in length. siRNA targeting 
sequence for hSpt5 was selected from position 407 to 427 relative to the start codon. As a specific control, mutant siRNA 
containing 2 nucleotide mismatches (underline) between the target mRNA and the antisense of siRNA at the hypothetical 
cleavage sites of the mRNA was generated. (B) Evaluation of specific hSpt5 siRNA activity by RT-PCR. Total cellular mRNA 
was prepared from HeLa cells transfected without siRNA or with hSpt5 duplex or control siRNAs and was followed by RT-
PCR, as described in Material and Methods. Each RT-PCR reaction included 100 ng total cellular mRNA, gene-specific primer 
sets for hSpt5 and hCycT1 amplification (0.5 µM for each primer), 200 µM dNTP, 1.2 mM MgSO4 and 1U of RT/platinum Taq 
mix. Primer sets for hSpt5 produced 2.6 kb products while hCycT1 produced 1.8 kb products. RT-PCR products were 
resolved on a 1% agarose gel and viewed by ethidium bromide staining. RT-PCR products are shown from cells that were not 
transfected with siRNA (lane 1), or cells transfected with single-stranded antisense hSpt5 siRNA (hSpt5 (AS), lane 2), hSpt5 
duplex siRNA (hSpt5 (DS), lane 3), or mismatch hSpt5 duplex siRNA (hSpt5-mm (DS), lane 4). Lane M is a marker lane. (C) 
Analysis of specific hSpt5 siRNA activity by western blotting. Cell lysates were prepared from HeLa cells mock-transfected 
without siRNA (lane 1), or transfected with single-stranded antisense hSpt5 siRNA (hSpt5 (AS), lane 2), hSpt5 duplex siRNA 
(hSpt5 (DS), lane 3), or mismatch hSpt5 duplex siRNA (hSpt5-mm (DS), lane 4). Cell lysates were analyzed by 10% SDS-PAGE. 
Protein contents were detected by immunoblotting assay with antibodies against hSpt5 (top panel) and hCycT1 (lower panel).
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that HCE is an essential enzyme for cell viability and
growth. Simialr findings showing that RNA capping was
essential for metazoan viability have also been previously
reported using RNAi in C. elegans [58]. These results indi-
cated that hSpt5 knockdown was not lethal to human
cells, while a much more stringent requirement for HCE
expression was essential for cell viability.
Role of hSpt5 on HIV-1 Tat Transactivation
To examine whether hSpt5 was required for HIV-1 Tat
transactivation in vivo, Tat transactivation during hSpt5
knockdown in Magi cells was monitored. Magi cells are a
HeLa cell line harboring a stably integrated single copy of
the HIV-1 5' LTR-β-galactosidase gene. These cells are also
genetically programmed to express the CD4 receptor for
HIV-1 infection ([59]; see below). In this experiment,
Magi cells were co-transfected with Tat expression plasmid
pTat-RFP and hSpt5 duplex siRNA. Co-transfection with
Tat siRNA was used as a positive control for inhibition of
Tat transactivation while single-stranded antisense hSpt5
siRNA and mismatched siRNA were used as negative con-
trols. Tat transactivation and protein levels were evaluated
by harvesting cells 48 h post transfection, which was
within the timeframe that hSpt5 knockdown peaked.
Expression of HIV-1 Tat-RFP under the control of the CMV
early promoter was confirmed by western blot using anti-
RFP antibody and by measuring RFP fluorescence using a
fluorescence spectrophotometer (data not shown). In
addition, immunoblot analysis confirmed that hSpt5
siRNA specifically inhibited hSpt5 protein expression in
the absence and presence of HIV-1 Tat protein in Magi
cells (data not shown).
Tat-RFP enhances the expression of genes that are under
the control of the HIV-1 5' LTR promoter. In this experi-
ment, Tat transactivation was measured by assaying the β-
galactosidase activity resulting from expression of the β-
galactosidase gene under the HIV-1 5' LTR promoter. To
quantify the effects of various siRNAs on HIV-1 Tat trans-
activation, the ratio between β-galactosidase activity in
cells transfected with pTat-RFP (with or without siRNAs)
and mock-treated cells not transfected with pTat-RFP was
determined. The results of this quantitation are shown in
Figure 4. In Magi cells, Tat-RFP strongly stimulates the
expression of β-galactosidase, represented by a 13-fold
increase in Tat transactivation (Figure 4, lane 1). On the
other hand, Tat transactivation was strongly inhibited in
cells transfected with Tat siRNA (~90% knockdown; Fig-
ure 4, lane 5), as previously shown [51]. Tat transactiva-
tion was similarly inhibited when cells were transfected
with hSpt5 duplex siRNA, exhibiting only ~30% of the Tat
transactivation observed with Tat-RFP alone (Figure 4,
lane 3). Neither antisense hSpt5 siRNA nor mismatched
hSpt5 siRNA (Figure 4, lane 4) showed any effect on Tat
transactivation. These results indicated hSpt5 knockdown
caused by siRNA specifically targeting hSpt5 mRNA inhib-
ited HIV-1 Tat transactivation in human cells. These
results strongly supported an important role for hSpt5 in
Tat transactivation in vivo and suggested that RNAi of
hSpt5 had the potential to inhibit HIV-1 replication.
Kinetics of specific hSpt5 siRNA activity by Western blottingF gure 2
Kinetics of specific hSpt5 siRNA activity by Western blotting. HeLa cells were transfected with single-stranded anti-
sense hSpt5 siRNA (hSpt5 (AS), lanes 1–7), hSpt5 duplex siRNA (hSpt5 (DS), lanes 8–14), or mismatch hSpt5 duplex siRNA 
(hSpt5-mm (DS), lanes 15–21) having 2 nucleotide mismatches between the target mRNA and the antisense strand of siRNA at 
the hypothetical cleavage site of the mRNA. Cells were harvested at various times post transfection. Protein content was 
resolved on 10% SDS-PAGE, transferred onto PVDF membranes, and immunoblotted with antibodies against hSpt5 (top 
bands) and hCycT1 as an internal control (lower bands).
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hSpt5 knockdown inhibits HIV-1 replication
To evaluate the effect of hSpt5 knockdown on HIV-1 rep-
lication, a double siRNA transfection protocol was used to
maximize the knockdown efficiency of hSpt5 during HIV-
1 infection. Magi cells were transfected with siRNA
directed against hSpt5. Cells mock transfected without
siRNA, or transfected with single-stranded antisense
hSpt5 siRNA or mismatch hSpt5 siRNA were used as neg-
ative controls. Transfection with Vif or Nef siRNAs was
used as a positive control [20]. 24 h after the first transfec-
tion, a second siRNA transfection identical to the first was
performed. 24 h later, doubly transfected cells were
infected with various concentrations of HIVNL-GFP, an
infectious molecular clone of HIV-1. Knockdown of hSpt5
protein levels was then evaluated 48 h post infection in
doubly transfected cells. An even larger decrease in hSpt5
protein levels was observed in doubly transfected cells
(~95% knockdown) as compared to singly transfected
cells (~85–90% knockdown; Supplementary Figure 1,
compare lanes 4 and 10), suggesting that more robust
knockdown of gene expression can be achieved using this
double transfection method.
HIV-1 Tat-mediated transactivation of the 5' LTR occur-
ring in cells infected with virus led to β-galactosidase pro-
duction, which was also quantified 48 h post-infection. In
this single-cycle replication assay for evaluating HIV-1
replication, β-gal activity reflected the activity of reverse
transcriptase and viral replication of varying amounts of
viral inoculum. Therefore, changes in β-gal activity could
be directly correlated to changes in the efficacy of HIV-1
replication. The positive siRNA control targeting HIV-1 Vif
showed decreased levels of β-gal activity and HIV-1 repli-
cation, as shown previously (Figure 5; [47]). Double-
Analysis of cell viability by counting trypan blue-stained cellsFigure 3
Analysis of cell viability by counting trypan blue-stained cells. HeLa cells were transfected with Lipofectamine with 
various siRNAs or no siRNA. Three siRNA duplexes, including hSpt5 siRNA (yellow), mismatch hSpt5 siRNA (light blue) and 
siRNA targeting human capping enzyme (HCE, red), were used in these experiments. Controls for viability included cells 
mock-transfected with no siRNA (dark blue) or cells transfected with single-stranded antisense hSpt5 siRNA (purple). At vari-
ous times after transfection, cells floating in the medium were collected and counted in the presence of 0.2% trypan blue. Cells 
that took up dye (stained blue) were counted as not viable.
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Effect of hSpt5 siRNA on HIV-1 Tat transactivation in Magi cellsFigure 4
Effect of hSpt5 siRNA on HIV-1 Tat transactivation in Magi cells. Quantified effect of siRNA on HIV-1 Tat transactiva-
tion was determined by measuring β-galactosidase activity. Magi cells were co-transfected with pTat-RFP plasmid and various 
siRNAs targeting hSpt5 or Tat and harvested at 48 h post-transfection. Activity of β-galactosidase was measured using the β-
Galactosidase Enzyme Assay System (Promega). Tat transactivation was determined by the ratio of β-galactosidase activity in 
pTat-RFP transfected cells to activity measured in cells without pTat-RFP. The inhibitory effect of siRNA was determined by 
normalizing Tat transactivation activity to the amount of Tat-RFP protein. Tat transactivation was measured for Magi cells 
transfected with pTat-RFP only (lane 1), or Tat-RFP transfected with single-stranded antisense hSpt5 siRNA (hSpt5-AS, lane 2), 
hSpt5 duplex siRNA (hSpt5-DS, lane 3), mismatch hSpt5 duplex siRNA (hSpt5-mm-DS, lane 4), or Tat siRNA duplex (Tat-DS, 
lane 5). Results are representative of three independent experiments.
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stranded siRNA directed against hSpt5 showed a similar
decrease in β-gal activity when compared with Vif knock-
down. This observed decrease was equivalent to the β-gal
activity measured when using 32 times less viral inoculum
with mock-treated cells (Figure 5), indicating that hSpt5
knockdown had significantly reduced HIV-1 replication.
p24 levels were also monitored during these experiments
and decreased in the context of hSpt5 knockdown (data
not shown), supporting the conclusion that hSpt5 knock-
down has a negative effect on the HIV-1 life cycle. Control
experiments using hSpt5 single-stranded antisense or mis-
matched duplex siRNA duplexes showed no antiviral
activities. In addition, no significant toxicity or cell death
was observed during these experiments, suggesting that
hSpt5 knockdown was not lethal even in the context of
HIV-1 infection. These results demonstrated that hSpt5
silencing using RNAi modulated HIV-1 replication and
firmly established an important role for hSpt5 in Tat
transactivation and HIV-1 replication in vivo.
Discussion
hSpt5, as part of the DSIF complex, was originally discov-
ered as a negative elongation factor required for confer-
ring DRB sensitivity to transcription elongation
complexes thereby inhibiting transcription [9]. This nega-
tive barrier provided by hSpt5 was thought to be relieved
siRNA targeting hSpt5 modulate HIV-1 replicationFigure 5
siRNA targeting hSpt5 modulate HIV-1 replication. HeLa-CD4-LTR/β-galactosidase (Magi) cells were mock-transfected 
(mock), or transfected with single-stranded antisense hSpt5 siRNA (AS), hSpt5 duplex siRNA (siRNA), mismatched hSpt5 
duplex siRNA (MM) or Vif duplex siRNA (T98). 24 h after the first transfection, a second siRNA transfection was performed. 
24 h later, cells were infected with HIVNL-GFP, an infectious molecular clone of HIV-1. Cells infected with virus and not treated 
with oligofectamine are shown (mock). HIV-1 Tat-mediated transactivation of the 5' LTR led to β-galactosidase production, 
which was quantified 48 h post-infection. Cells treated with duplex siRNA targeting Vif (lanes marked T98 [47]) served as a 
positive control. Serial double dilutions of the viral inoculum (in cpm of RT activity) are consistent with 32-fold decreases in 
viral replication.
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through P-TEFb phosphorylation of both hSpt5 and RNA
pol II CTD, which results in increased processivity of RNA
pol II complexes [7,10,21-29]. Increased processivity has
also been linked to the phosphorylated form of hSpt5
conferring a positive effect on transcription elongation
[25,29,34]. Recently, however, it has been shown that Tat
is able to enhance transcription elongation in vitro in the
absence of hSpt5 [26]. These results appeared to indicate
that P-TEFb phosphorylation of RNA pol II was the sole
event that directly led to Tat transactivation and increased
RNA pol II processivity [26]. Thus, from the results of all
of these in vitro studies collectively, the requirement for
hSpt5 in positively regulating transcription elongation
during Tat transactivation has remained unclear.
Here, we studied the role of hSpt5 in vivo using RNAi and
established that hSpt5 played a positive role in Tat trans-
activation and HIV-1 replication. Knockdown of hSpt5
provided insight into several functional aspects of the
hSpt5 protein. First, knockdown of hSpt5 was not lethal
in Magi cells, indicating that hSpt5 was not required for
cell viability. This was an interesting result because studies
of SPT5 mutants in yeast and zebrafish and RNAi of SPT5
in C. elegans have shown that SPT5 was essential for
growth and/or embryonic development in those organ-
isms [30,31,60]. It seems likely that hSpt5 holds similar
essential functions in human cells during embryonic
development but may not be absolutely required in adult
cells. Alternatively, hSpt5 knockdown may have led to
decreased levels of expression that were still sufficient for
hSpt5 to carry out its essential functions. Our results sup-
port the notion of using RNAi against hSpt5 as a potential
therapeutic strategy for fighting HIV-1 infection since
there is the potential that HIV-1 functions could be tar-
geted for inhibition without significantly interfering with
host cell functions.
The key finding of this study was that hSpt5 knockdown
significantly inhibited both Tat transactivation and HIV-1
replication. These results indicated that hSpt5 was a bona
fide regulator of Tat transactivation that is required for
HIV-1 replication in vivo. Our in vivo results strongly sup-
port previous in vitro results recapitulating Tat transactiva-
tion that showed immunodepletion of hSpt5 significantly
inhibited Tat transactivation [29,34]. However, it is diffi-
cult to reconcile our in vivo results with recently published
in vitro experiments showing that P-TEFb hyperphosphor-
ylation of the CTD in the absence of hSpt5 still enhanced
RNA pol II processivity during Tat transactivation [26]. In
reconciling whether P-TEFb hyperphosphorylation was
directly required for Tat transactivation to the exclusion of
hSpt5, we would like to propose that the required func-
tion of P-TEFb hyperphosphorylation may be distinct
from the role hSpt5 plays in enhancing RNA pol II proces-
sivity during Tat transactivation. In our model (Figure 6),
P-TEFb hyperphosphorylation would occur first, trigger-
ing enhanced processivity of RNA pol II. hSpt5 presuma-
bly is phosphorylated at around the same time as RNA pol
II, stimulating hSpt5 to switch from a negative regulator to
a positive elongation factor [25]. Phosphorylated hSpt5
may then be important for positively regulating an initial
step in Tat transactivation.
Conceivably, hSpt5 functions in transcription elongation
as a stabilization factor that enhances the stability of RNA
pol II elongation complexes formed after P-TEFb hyper-
phosphorylation of the CTD. This type of role would also
support hSpt5 function as an antiterminator factor as
described previously [61]. Another important positive
function for hSpt5 during Tat transactivation may involve
hSpt5 and Tat interactions with the capping machinery
[40-42]. Phosphorylation of hSpt5 by P-TEFb may stabi-
lize hSpt5 interactions with HCE thereby stabilizing Tat
and CTD interactions with the capping machinery to pro-
mote capping and successful production of stable HIV
transcripts (see model in Figure 6). Due to the highly
structured nature of TAR, capping of the 5' end of HIV
transcripts is not very efficient in the absence of Tat
[41,42] and Tat stimulated capping may require the pres-
ence of hSpt5 for greater access to the 5' end or to stabilize
and kinetically arrest the elongation complex. Capping of
HIV transcripts has also been shown to occur more profi-
ciently when elongation is paused and not continuous
[42], suggesting that DSIF/NELF-dependent pausing of
early stage elongation complexes is representative of an
elongation checkpoint. One function of this checkpoint
may be to allow time for the recruitment of capping
machinery and subsequent capping of HIV RNA to stabi-
lize nascent transcripts prior to further elongation. In the
absence of hSpt5, pausing may no longer occur during
elongation since neither NELF nor hSPT4 binds to RNA
pol II without hSpt5 [62,63]. Thus, the window for the
capping apparatus to be recruited by Tat and/or stimulate
capping may be severely shortened or lost altogether with-
out hSpt5. Any resulting uncapped HIV transcripts would
be prone to degradation, accounting for the lower level of
Tat transactivation and HIV replication observed during
hSpt5 knockdown. The potential roles for phosphorylated
hSpt5 in stabilizing RNA pol II processive elongation
complexes or with respect to capping during Tat transacti-
vation are not mutually exclusive as shown in Figure 6.
hSpt5 may indeed have multi-functional roles as a posi-
tive regulator during HIV-1 replication.
Conclusions
The in vitro and in vivo approaches taken to address the
importance of hSpt5 function all shed light on the multi-
faceted nature of Tat transactivation. Accordingly, these
studies altogether support important roles for both P-
TEFb and hSpt5 in mediating transcription elongation
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during HIV-1 replication in vivo. The dual function of
hSpt5 as a negative and positive transcription elongation
factor also demonstrates the complexity associated with
transcriptional regulation during transcription elongation
and HIV-1 Tat transactivation. It is likely that posttransla-
tional modifications of hSpt5 dictate functions of Spt5 at
various promoters. Further studies will be required to elu-
cidate how various modifications of hSpt5 such as
phosphorylation and methylation control transcription
elongation of both cellular and viral genes.
Methods
siRNA preparation
Twenty-one nucleotide siRNAs were chemically synthe-
sized as 2' bis(acetoxyethoxy)-methyl ether-protected oli-
gos (Dharmacon, Lafayette, CO). Synthetic RNAs were
deprotected, annealed and purified using standard proto-
cols provided by the manufacturer. Formation of duplex
RNA was confirmed by 20% non-denaturing polyacryla-
mide gel electrophoresis (PAGE). Sequences of siRNA
duplexes were designed as described previously [46] and
subjected to a BLAST search against the NCBI EST library
to ensure that only the desired genes were targeted.
Culture and transfection of cells
Magi (multinucleate activation of galactosidase indicator)
cells carrying the endogenous HIV-5'LTR β-galactosidase
gene were maintained at 37°C in Dulbecco's modified
Eagle's medium (DMEM, Invitrogen) supplemented with
10% fetal bovine serum (FBS), 0.2 mg/ml of Geneticin
Model for Tat transactivation in absence or presence of SPT5Figure 6
Model for Tat transactivation in absence or presence of SPT5. See text for details.
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(G418) and 0.1 mg/ml Hygromycin B (Roche Molecular
Biochemicals). Cells were passaged at sub-confluence and
plated at 70% confluency for transfection. Reporter plas-
mids and siRNA were co-transfected into Magi cells using
Lipofectamine (Invitrogen) in duplicate 6-well plates (Fal-
con). A transfection mixture containing 25–150 nM
siRNA and 9 µl of Lipofectamine in 1 ml of serum-reduced
OPTI-MEM (Invitrogen) was added to each well. For high
efficiency knockdown experiments, 150 nM siRNA was
used. After incubating at 37°C for 6 h, cells were cultured
in antibiotic-free DMEM. For further analysis, transfected
cells were harvested at various time intervals, washed
twice with phosphate buffered saline (PBS, Invitrogen),
flash frozen in liquid nitrogen, and stored at -80°C.
RT-PCR for amplification of hSpt5 and hCycT1 mRNA
Total cellular mRNA was prepared from HeLa cells trans-
fected without siRNA or with hSpt5 or control siRNAs
using a Qiagen RNA mini kit, followed by an oligotex
mRNA mini kit (Qiagen). RT-PCR was performed using a
SuperScript One-Step RT-PCR kit with platinum Taq (Inv-
itrogen) and 40 cycles of amplification. Each RT-PCR reac-
tion included 100 ng total cellular mRNA, gene-specific
primer sets for hSpt5 and hCycT1 amplification (0.5 µM
for each primer), 200 µM dNTP, 1.2 mM MgSO4 and 1U
of RT/platinum Taq mix. Primer sets for hSpt5 produced
2.6 kb products while hCycT1 produced 1.8 kb products.
RT-PCR products were resolved on a 1% agarose gel and
viewed by ethidium bromide staining. Forward and
reverse primer sequence for amplifying SPT5 were 5'-
ATGTCGGACAGCGAGGACAGC-3' (nts 1–21) and 5'-
TGTACATGGCCGGCGTCCC-3' (nts 2638–2656), respec-
tively. Forward and reverse primer sequences for amplify-
ing hCycT1 are 5'-GCAACAAGTTCAAGATCTGGTCAT-3'
(nts 381–404) and 5'-CCCGGGGGATCCTTACTTAG-
GAAGGGGTGGAAGTGG-3' (nts 2158–2200); under-
lined sequences represent restriction enzyme sites),
respectively.
Western blotting
siRNA treated cells were harvested as described above and
lysed in 1X reporter lysis buffer (Promega). After centrifu-
gation to remove cellular debris, concentrations of pro-
teins in lysates were determined using a Dc protein assay
kit (Bio-Rad). Proteins in 30 µg of total cell lysates were
fractionated by 10% SDS-PAGE, transferred onto a
polyvinylidene difluoride membrane (PVDF membrane,
Bio-Rad), and immunoblotted with antibodies against
hSpt5 (Pharmingen) and hCycT1 (Santa Cruz Biotech).
Protein content was visualized by a BM chemilumines-
cence Blotting Kit (Roche Molecular Biochemicals). The
blots were exposed to X-ray film (Kodak MR-1) for various
times (between 1 s and 5 min).
β-galactosidase enzyme assay
Magi cells were harvested 48 h after transfection with Tat-
RFP plasmids in the absence or presence of siRNAs. Cell
lysates were prepared and quantified as described above.
To perform standard β-galactosidase assays, 120 µg of cell
lysates were mixed in 150 µl of 1X reporter lysis buffer and
150 µl of 2X β-galactosidase assay buffer (Promega), and
incubated at 37°C for 30 min. To stop the reaction, 500
µl of 1 M sodium carbonate was added to the mixture and
mixed well by vortexing briefly. Absorbance of the reac-
tion mixture was read immediately at 420 nm. The
amount of Tat-RFP protein was determined using a fluo-
rescence spectrophotometer (Photon Technology Interna-
tional). 300 µg of cell lysates was subjected to the
spectrophotometer with slit widths set at 4 nm for both
excitation and emission wavelengths as described previ-
ously [46,64]. Fluorescence of Tat-RFP in the cell lysate
was detected by exciting at 558 nm and recording the
emission spectrum from 568 nm to 650 nm; the spectrum
peak at 583 nm represents the maximum fluorescence
intensity of Tat-RFP. Tat transactivation was determined
by calculating the ratio of β-galactosidase activity (absorb-
ance at 420 nm) of the pTat-RFP transfected cells to that
of cells without pTat-RFP plasmid treatment. The inhibi-
tory effect of siRNA treatment was determined by normal-
izing Tat-transactivation activity to the amount of Tat-RFP
protein (represented by RFP fluorescence intensity) in the
presence and absence of siRNA.
Magi infectivity assay
HeLa-CD4-LTR/β-gal indicator (Magi) cells [59] were
plated in 24-well plates (7.5 × 105 cells per well) and
transfected with siRNAs as previously described [47].
siRNA (60 pmol) was transfected into cells using oligo-
fectamine (2 µl, Invitrogen) for 3 h in serum-free DMEM
(GIBCO). Cells were rinsed twice and top-layered in 500
µl of DMEM-10% FBS. 24 h after the first transfection, a
second identical siRNA transfection was performed. 24 h
after the second transfection, cells were trypsinized and
seeded in 96-well microtiter plates (4 × 104 cells per well),
incubated 3 h and infected with HIVNL-GFP, an infectious
molecular clone of HIV-1. HIV-1 virions (normalized to
RT activity in cpm) were added in doubling dilutions to
duplicate wells. 48 h post infection, cells were harvested
to quantify β-galactosidase activity and protein levels.
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